Summit Therapeutics (SMMT) traded higher Friday as the market continued to price in updated Phase III ivonescimab datasets tied to the European Lung Cancer Congress (ELCC) 2026 cycle, where the company highlighted multiple poster presentations in advanced non-small cell lung cancer (NSCLC). Attention has centered on the company’s discussion of intracranial outcomes in patients with baseline brain metastases, a high-value subgroup that can influence physician adoption and payer perception if the benefit is durable. (smmttx.com)

Ivonescimab is positioned as a potential first-in-class PD-1 × VEGF bispecific, and investors have been looking for evidence that it can differentiate not only on systemic progression-free outcomes but also in harder-to-treat settings such as brain metastases. The ELCC materials and related disclosures kept that narrative active in the tape, supporting incremental buying after earlier volatility in the name. (smmttx.com)

Separately, the company’s near-term fundamental anchor is its U.S. filing status: the FDA has accepted Summit’s BLA for ivonescimab in NSCLC and set a PDUFA goal date of November 14, 2026. With that date still months away (as of April 17, 2026), day-to-day moves are likely to be driven by shifting expectations around additional Phase III updates, medical-meeting follow-through, and the perceived strength of the approval package. (finance.yahoo.com)